Organon & Co. logo

Organon & Co.

OGN
HealthcareNYSEUnited States
6.06USD-0.03 (-0.49%)

About Organon

Organon & Co. is a global healthcare company that develops and delivers prescription therapies across a broad range of therapeutic areas.

The company serves drug wholesalers and retailers, hospitals, government agencies, and managed care providers.

  • Women’s Health: Nexplanon/Implanon (long-acting reversible contraception), fertility treatments

  • Biosimilars: Brenzys, Renflexis, Hadlima (immunology), Ontruzant, Aybintio (oncology)

  • Cardiovascular: Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor (cholesterol-modifying therapies), Cozaar, Hyzaar (hypertension)

  • Respiratory & Allergy: Singulair, Dulera, Zenhale, Asmanex (asthma), Nasonex, Clarinex, Aerius (seasonal allergic rhinitis)

  • Dermatology: Diprosone, Elocon (topical skin treatments)

  • Bone Health: Fosamax (osteoporosis)

  • Pain Management: Arcoxia, Diprospan, Celestone (non-opioid treatments for inflammation and pain)

  • Urology & Men’s Health: Proscar (benign prostatic hyperplasia), Propecia (male pattern hair loss)

Organon was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Organon's Business Strategy

Organon's core strategy is to establish itself as a global leader focused on improving Women's Health throughout their lives, complemented by portfolios in Biosimilars and Established Brands.

​As a standalone company since its spin-off from Merck in June 2021, Organon aims to leverage its global leadership…

Available on Finplify

Free account required

Sign up free

Our Take on Organon

Pros:

Women’s Health Exposure: It is a global leader in contraception and fertility products, with well-known brands like Nexplanon and Follistim, offering stable demand and long product life cycles.

Biosimilars Expansion: Organon is expanding its biosimilars portfolio, with plans to launch a biosimilar for…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NYSE
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joseph T. Morrissey Jr.
Employees
10,000
IPO Date
2021-05-14
ISIN
US68622V1061
Website
organon.com

Key Metrics

Market Cap
1.58BUSD
P/E Ratio (TTM)
8.47
Net Profit Margin
3.01%
Debt / Asset Ratio
0.68
Dividend Yield (TTM)
1.31%
Volume
327,059
Avg Volume
5.44M
Shares Outstanding
259.98M
Free Float
99.60%
β Beta
0.55
52W Range
5.8 - 15.8

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
2.6/5Average
Liquidity
3.2/5Average
Leverage
1.5/5Poor
Cash Flow
5.0/5Excellent
Valuation
4.9/5Excellent

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on Organon

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.